OSAKA, Japan, April 3, 2023, – Takeda (TSE:4502/NYSE:TAK) today announced that the Takeda Resource Group (TRG) TAKE PRIDE Japan will participate in Tokyo Rainbow Pride 2023 (April 22–23), organized by the NPO Tokyo Rainbow Pride. For the first time, the TRG will also have a booth at the event.
Members of TAKE PRIDE Japan, together with any other employees who wish to join, will be able to take part in the Pride Parade on April 23. This is the third time the TRG will have a presence at the parade following the 2018 and 2019 events.
The Pride Parades, which are events held to celebrate sexual minorities, are held every year in major cities in Europe, the United States and many other countries around the world. In Japan, the Pride Parade is held around the Golden Week holidays. In recent years, the term SOGI (Sexual Orientation and Gender Identity) is gaining currency as a more inclusive term than LGBTQ+.
Takeda’s LGBTQ+ focus not only on company-centered activities, but also on TRG-centered activities. During Pride Month in June and on Coming Out Day in October, TAKE PRIDE Japan hosted events for employees to raise awareness and learn about LGBTQ+ issues. It also held various internal and external activities with like-minded groups at other companies throughout FY2022.
To realize our vision of contributing to patients around the world, Takeda has positioned DE\&I as a growth strategy, working to create an inclusive organization in which our diverse employees can all play an active role. In recognition of this, we received the highest “Gold” rating in the PRIDE Index for the second year in a row for our domestic LGBTQ+ activities, which are part of the company’s global DE\&I goals.
For more information on our DE\&I initiatives, please visit our website.
https://www.takeda.com/ja-jp/recruitment/dei
About Takeda
Takeda is a global, values-based, R\&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R\&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R\&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R\&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
Media Contacts:
Tatsuhiro Kanoo
+81 3-3278-3634